Jury awards $5 million in HRT-breast cancer case 
By:
Sylvia Hsieh
Published: September 21, 2012
Tags: breast cancer, drug litigation, hormone replacement therapy, HRT, HRT litigation, Pfizer, Prempro, product liability, Provera, Upjohn, Wyeth
A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.
Prempro expert could testify regarding short-term use
Published: July 30, 2012
Tags: breast cancer, Daubert, expert witness, hormone replacement therapy, Prempro, Wyeth
Product liability plaintiffs should have been permitted to introduce expert testimony linking the short-term use of Prempro to a risk of breast cancer, the 8th Circuit has ruled in reversing a summary judgment.
Reglan most litigated drug of 2011, latest ranking says
Published: June 7, 2012
Tags: Accutane, adverse events, Avandia, Bayer, Chantix, Coumadin, drug litigation, FDA, Food and Drug Administration, GlaxoSmithKline, Hoffman-LaRoche, Institute for Safe Medication Practices, Johnson & Johnson, Levaquin, Pfizer, Pradaxa, prescription drugs, Reglan, Wyeth, Yasmin, Yaz
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
Woman wins $4 million in Prempro breast cancer trial
By:
Sylvia Hsieh
Published: April 27, 2012
Tags: breast cancer, drug litigation, hormone replacement therapy, HRT litigation, Pfizer, Prempro, Wyeth
A 65-year-old elementary school principal has won a $4 million verdict in Connecticut federal court against the maker of the menopause drug Prempro for causing her breast cancer.
Prempro plaintiff can’t show causation, District Court rules
Published: March 13, 2012
Tags: breast cancer, causation, failure to warn, hormone replacement therapy, Premarin, Prempro, product liability, Provera, Upjohn, Wyeth
A product liability plaintiff could not show that the alleged failure of pharmaceutical companies to warn about the dangers of their hormone therapy drugs was the proximate cause of her breast cancer, a U.S. District Court in South Carolina has ruled in granting summary judgment.
HRT drug claim isn’t barred by prior bankruptcy
Published: February 24, 2012
Tags: cancer, hormone replacement therapy litigation, Prempro, product liability, Wyeth
A product liability lawsuit against drug maker Wyeth was not barred by the plaintiff’s failure to declare her claim as an asset in her bankruptcy case prior to obtaining a discharge of debts, a U.S. District Court in Mississippi has ruled in denying summary judgment.
Pa. court reinstates $28M punitive award in HRT case
Published: January 10, 2012
Tags: breast cancer, HRT litigation, Premarin, Prempro, product liability, Provera, Upjohn, Wyeth
A $28 million award of punitive damages was not unconstitutionally excessive in a product liability case brought by a woman who contracted breast cancer after taking hormone replacement therapy drugs, a Pennsylvania appellate court has ruled in reversing judgment.
Wyeth’s marketing efforts admissible in Prempro case
Published: January 10, 2012
Tags: breast cancer, HRT litigation, Prempro, product liability, Wyeth
Evidence of Wyeth’s marketing campaign for “off-label” Prempro uses was admissible in a product liability case brought by a woman who contracted breast cancer after taking the drug, a Pennsylvania appellate court has ruled.
Wyeth accused of using sham patents to stop generic Effexor
Published: July 13, 2011
Tags: antitrust, Effexor XR, generic drugs, patent litigation, Pfizer, Wyeth
An antitrust lawsuit filed in federal court in Mississippi alleges that Wyeth Pharmaceuticals used fraudulently obtained patents as part of a scheme to delay the introduction of generic versions of the anti-depressant Effexor XR.
Prempro verdict, punitive award reinstated on appeal
Published: June 15, 2011
Tags: Prempro, product liability, Wyeth
A jury’s $1.6 million verdict for the plaintiff in a Prempro case should be reinstated along with a sealed punitive award against drugmaker Wyeth, a Pennsylvania appellate court has ruled.
